Nilotinib and Imatinib Are Comparably Effective in Reducing Growth of Human Eosinophil Leukemia Cells in a Newly Established Xenograft Model

• Daniel Wicklein ,

  Contributed equally to this work with: Daniel Wicklein, Nuno Ramos Leal

  * E-mail: d.wicklein@uke.de

  Affiliations Institute of Anatomy and Experimental Morphology, University Cancer Center, University Medical-Center Hamburg-Eppendorf, Hamburg, Germany, Institute of Clinical Chemistry, University Medical-Center Hamburg-Eppendorf, Hamburg, Germany

  ⨯
• Nuno Ramos Leal ,

  Contributed equally to this work with: Daniel Wicklein, Nuno Ramos Leal

  Affiliation Institute of Anatomy and Experimental Morphology, University Cancer Center, University Medical-Center Hamburg-Eppendorf, Hamburg, Germany

  ⨯
• Johannes Salamon,

  Affiliation Department of Radiology, University Medical-Center Hamburg-Eppendorf, Hamburg, Germany

  ⨯
• Mohammed Thamer,

  Affiliation Institute of Anatomy and Experimental Morphology, University Cancer Center, University Medical-Center Hamburg-Eppendorf, Hamburg, Germany

  ⨯
• Harald Herrmann,

  Affiliation Ludwig-Boltzmann Cluster Oncology, Vienna, Austria

  ⨯
• Peter Valent,

  Affiliations Ludwig-Boltzmann Cluster Oncology, Vienna, Austria, Division of Hematology and Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria

  ⨯
• Udo Schumacher,

  Affiliation Institute of Anatomy and Experimental Morphology, University Cancer Center, University Medical-Center Hamburg-Eppendorf, Hamburg, Germany

  ⨯
• Sebastian Ullrich

  Affiliation Institute of Anatomy and Experimental Morphology, University Cancer Center, University Medical-Center Hamburg-Eppendorf, Hamburg, Germany

  ⨯